Authors: Patrick R Lawler, Ewan C Goligher, Jeffrey S Berger, Matthew D Neal, Bryan J McVerry, Jose C Nicolau, et al.

PMID: 34351721 PMCID: PMC8362594 DOI: 10.1056/NEJMoa2105911

Abstract

Background: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.

Methods: In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical